BioSpace News Archive

Primary efficacy endpoint met with 87.7% response rate at one year; women experienced, on average, an 89.9% reduction in menstrual blood loss Bone mineral density maintained through one year, with no new safety signals Data further strengthen the New Drug Application (NDA) expected to be submitted in April 2020 BASEL, Switzerland, Feb. 10, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on developing innovative treatments for women’s health a

Awards for achievement in the contact lens field were presented recently to three team members of Innovega, a company engaged in developing stylish, lightweight, wearable display technology with a panoramic field of view for virtual and augmented reality

REDWOOD CITY, Calif., Feb. 10, 2020 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute” or “the Company”) (OTCQB:RZLT), today announced the initiation of the RIZE study (RZ358-606), a Phase 2b clinical trial of its lead candidate, RZ358, in patients with congenital hyperinsulinism (CHI). The Company has screened the first patient and expects to make significant enrollment progress to enable attainment of mid-study results over the coming year. “Congenital hyperinsulinism is the most common cau

- 96.7% response rate in Phase 3 HERO study support submission of New Drug Application (NDA) for relugolix monotherapy tablet for advanced prostate cancer in the second quarter of calendar year 2020 - 87.7% one-year response rate in LIBERTY open-label extension study supports submission of NDA for relugolix combination tablet for women with heavy menstrual bleeding associated with uterine fibroids in April 2020 - Enrollment completed in Phase 3 SPIRIT 2 and SPIRIT 1 studies in women w

Teladoc Health, Inc. (NYSE: TDOC), the global leader in virtual care, announced today that it will release fourth-quarter and full-year 2019 results on Wednesday, February 26th, 2020, after the market closes.

Citius Pharmaceuticals, Inc. (“Citius” or the “Company”) (NASDAQ: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, announced today that the Company will present at Noble Capital Markets’ 16th Annual Investor Conference on Monday, February 17, 2020 at 4:00 PM ET . The c

Presenting sponsor Eisai Inc. and METAvivor announce today that they have joined forces with AnaOno Intimates and #Cancerland to fearlessly unite the breast cancer community and shine a spotlight on metastatic breast cancer (MBC) while highlighting the #ThisIsMBC Beneath the Breast campaign through fashion, during New York Fashion Week.

Nautilus, Inc. (NYSE: NLS) today announced that the Company will report its financial results for the fourth quarter and full year ended December 31, 2019 after the market closes on February 24, 2020, followed by a management hosted conference call to discuss the Company’s operating results.

Zoetis Inc. (NYSE:ZTS) will participate in the Bank of America Merrill Lynch Animal Health Summit on Monday, Feb. 24, 2020, in New York, N.Y. Glenn David, Executive Vice President and Chief Financial Officer, will represent the company and respond to questions from analysts. He is scheduled to present at 8:40 a.m. ET.

Feb. 10, 2020 13:30 UTC -- If Approved, Kite Could be First Company with Multiple Commercialized CAR T Therapies -- SANTA MONICA, Calif.--( BUSINESS WIRE )-- Kite, a Gilead Company (Nasdaq: GILD), today announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) and granted Priority Review designation for KTE-X19, an investigational chimeric antigen receptor (CAR) T cell therapy for the treatment of adult patients with r